Oka suppositories Recto. 160mg 10 pieces


Oka suppositories Recto. 160mg 10 pieces



Active substance:
ketoprofen lysine salt 160 mg;
semisynthetic glycerides 1,640 mg
Suppositories from white to pale yellow torpedo-shaped.
Product form:
5 suppositories in a strip of Al-foil. 2 strips in a cardboard package with instructions for use
Hypersensitivity (including to other. NSAIDs), “Aspirin” asthma, gastric ulcer and 12-
duodenum (exacerbation), ulcerative colitis (exacerbation), Crohn’s disease, diverticulitis, peptic ulcer,
hemophilia and others. coagulation disorders, chronic renal failure, child (under 18 years), pregnancy (III trimester), lactation.
Precautions – anemia, bronchial asthma, alcoholism, smoking, alcoholic cirrhosis,
hyperbilirubinemia, hepatic failure, diabetes, dehydration, sepsis, chronic heart failure, edema, hypertension, blood diseases (including leukopenia), deficiency of glucose-6-phosphate dehydrogenase, stomatitis, advanced age, pregnancy (I, II trimester).
In case of deterioration of the patient’s condition should discontinue medication.
160 mg
Symptomatic treatment of inflammatory processes accompanied by fever and pain, including inflammatory and rheumatic diseases of the joints:
• rheumatoid arthritis • spondylitis osteoarthritis • • • gouty arthritis inflammatory lesion periarticular tissues
Interaction with other drugs
Inductors microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, flumetsinol, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of active hydroxylated metabolites.
Reduces the efficiency of uricosuric drugs, enhances the action of anticoagulants, antiplatelet agents, fibrinolytics, ethanol mineralkortikosteroidov side effects, glucocorticoids, estrogens.
Reduces the effectiveness of antihypertensive and diuretics.
Co-administration with other. NSAIDs, corticosteroids, ethanol, corticotropin may lead to the development of ulcers and gastrointestinal bleeding, increase the risk of renal functions.
Simultaneous with the appointment of oral anticoagulants, heparin, thrombolytics, antiplatelet, tsefaperazon, cefamandole and tsefotetanom increases the risk of bleeding.
Increases hypoglycemic effect of insulin and oral hypoglycemic agents (requires recalculation of the dose).
Co-administration of sodium valproate causes disturbance of platelet aggregation. Increases concentration of plasma verapamil and nifedipine, lithium preparations methotrexate. Antacids colestyramine and reduce absorption.
Currently, the cases of drug overdose were reported OCI
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug (NSAID).
Pharmacological properties:
It has anti-inflammatory, analgesic and antipyretic effect. Inhibiting cyclooxygenase type I and II, inhibits the synthesis of prostaglandins. Antibradikininovoy possesses activity stabilizes lysosomal membranes and inhibits the release of these enzymes that contribute to tissue destruction in chronic inflammation. It reduces the release of cytokines, inhibits the activity of neutrophils.
Reduce morning stiffness and swelling of joints, increases range of motion.
Ketoprofen lysine salt, unlike ketoprofen is rapidly dissolving molecule with a neutral pH and almost no irritation to the gastrointestinal tract.
Ketoprofen lysine salt is rapidly absorbed: time to reach maximum concentration (Tmax) after rectal administration of 45-60 minutes. The magnitude of the plasma concentration depends linearly on the dose.
Up to 99% of absorbed ketoprofen bound to plasma proteins, mainly albumin. The volume of distribution – 0.1-0.2 l / kg. Easily it passes through the blood-tissue barriers and distributed in the tissues and organs. Ketoprofen is well into the synovial fluid and connective tissue. While ketoprofen concentration in synovial fluid is somewhat lower than in the plasma, they are more stable (stored up to 30 hours).
Ketoprofen is mainly metabolized by the liver, where it undergoes glucuronidation to form esters with glucuronic kiclotoy.
Metabolites are mainly in the urine (76% after 24 hours). The drug does not accumulates.
Pregnancy and breast-feeding
As with other NSAIDs, the OCI shall not apply in the III trimester of pregnancy. Use of the drug in the I and II trimester should be closely monitored by the attending physician. Breast-feeding while using this drug should be discontinued.
Conditions of supply of pharmacies
By prescription.
side effects
Gastrointestinal tract: abdominal pain, diarrhea, duodenitis, erosive and ulcerative lesions of the gastrointestinal tract, gastritis, gematomezis, esophagitis, stomatitis, melena.
Liver: increase in bilirubin, increase in “liver” enzymes, hepatitis, hepatic failure, enlarged liver.
Nervous system: dizziness, hyperkinesia, tremor, vertigo, mood swings, anxiety, hallucinations, irritability, malaise.
Senses: conjunctivitis, blurred vision.
Skin: urticaria, angioedema, erythematous rash, itching, makulo-papular rash,
increased sweating, erythema multiforme (including Stevens-Johnson syndrome).
Urogenital: painful urination, cystitis, edema, hematuria, menstrual disorders.
Forming Organs: leykotsitopeniya, leukocytosis, lymphangitis, decrease of prothrombin time, purpura, thrombocytopenia, thrombocytopenic purpura, an increase in size of the spleen, vasculitis.
Respiratory system: bronchospasm, dyspnea, throat feeling spasm, laryngospasm, laryngeal edema, rhinitis.
Cardiovascular system: hypertension, hypotension, tachycardia, chest pain, syncope, peripheral edema, pallor.
Allergic reactions: anaphylactoid reactions, swelling of the mouth, throat edema, periorbital edema.
Local reactions: burning, itching, heaviness in the anorectal area, worsening of hemorrhoids.
special instructions
During treatment requires monitoring picture peripheral blood and functional state of the liver and kidneys.
If necessary, definition of 17-ketosteroids drug should be discontinued 48 hours before the study.
Acceptance of ketoprofen may mask signs of infection.
If the kidney and liver functions necessary to decrease the dose and careful observation. Use of ketoprofen patients suffering from bronchial asthma, can lead to attacks of bronchial asthma.
Women planning a pregnancy should refrain from taking the drug, because may reduce the likelihood of implantation of the egg.
Impact on the ability to drive vehicles and management mechanisms.
During the period of the drug should refrain from potentially dangerous activities associated with the need to concentration and rapid psychomotor reactions.
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children!
Dosing and Administration
One suppository 2-3 times a day. The maximum daily dose of 480 mg. Elderly patients should use no more than 2 suppositories per day.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review